|Title||Xanthohumol Microbiome and Signature in Healthy Adults (the XMaS Trial): Safety and Tolerability Results of a Phase I Triple-Masked, Placebo-Controlled Clinical Trial.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Langley BO, Ryan JJoan, Hanes D, Phipps J, Stack E, Metz TO, J Stevens F, Bradley R|
|Journal||Mol Nutr Food Res|
|Date Published||2021 04|
SCOPE: Xanthohumol, a prenylflavonoid from hops, has been extensively studied preclinically but has undergone limited research in human subjects. A triple-masked, placebo-controlled phase I clinical trial was conducted to examine the safety and tolerability of xanthohumol.
METHODS AND RESULTS: Thirty healthy volunteers were randomized to 24 mg day xanthohumol (99.8% pure) or placebo for eight weeks. Comprehensive metabolic panels, complete blood counts, body weight, vital signs, and health-related quality of life questionnaires were assessed every two weeks. Participants were interviewed for adverse events (AEs) throughout the trial. Thirteen of 14 (93%) and 14 of 16 (88%) participants completed the trial in the placebo and xanthohumol groups, respectively. There were no withdrawals due to AEs. There were no clinically relevant, between-group differences in laboratory biomarkers, body weight, vital signs, or health-related quality of life. There were no severe or FDA-defined serious AEs, but non-serious AEs are documented in both the placebo (n = 42) and xanthohumol (n = 58) groups.
CONCLUSION: Over an eight-week period, 24 mg daily xanthohumol was safe and well-tolerated by healthy adults.
|Alternate Journal||Mol Nutr Food Res|
|PubMed Central ID||PMC8221389|
|Grant List||R01 AT010271 / AT / NCCIH NIH HHS / United States|